Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s ...

Dr. Dajun Yang, Ascentage Pharma CEO, joins 'Closing Bell Overtime' to talk today's IPO. Marilyn Manson won’t face sexual ...

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Takeda-backed Ascentage Pharma Group (AAPG) (ASPHF), which is developing treatments for blood cancers, has set terms for a ...

Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.

Suzhou, China-based Ascentage Pharma revealed that it plans to raise $149 million by offering 7.3 million American Depositary ...

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...

Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...